The European Union (EU) has approved the contract that will provide a total of 1.8 billion doses, 900 million of which are optional, from the vaccine developed by BioNTech-Pfizer against the new type of corona virus (Covid-19).
EU Commission President Ursula von der Leyen announced on his social media account that a new contract has been signed with BioNTech-Pfizer for the purchase of Covid-19 vaccine.
Pointing out that the vaccination process is progressing well in Europe, Von der Leyen stated that additional doses will be used in immunity-boosting vaccines, in the fight against emerging new variants, and in vaccination of children and young people.
Von der Leyen noted that the EU Commission has approved a purchase agreement with BioNTech-Pfizer for the years 2021-2023 for a total of 1.8 billion doses of which 900 million doses are optional.
According to the German news agency, the EU will pay $ 43 billion for this contract.
The EU has so far, including options, to receive 2.4 billion doses with BioNTech-Pfizer, 400 million with AstraZeneca, 300 million with Sanofi-GSK, 400 million with Johnson & Johnson, 405 million with CureVac, 460 million with Moderna. has a contract.
Until now, vaccines produced by BioNTech-Pfizer, Moderna, AstraZeneca and Johnson & Johnson companies have received EU approval.
Considering these conventions, the EU administration aims to vaccinate 70 percent of the adult population in the EU, which has a population of 450 million during the summer months.